Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 96% Improvement Relative Risk HCQ for COVID-19  Heras et al.  EARLY TREATMENT Is early treatment with HCQ + AZ beneficial for COVID-19? Retrospective 100 patients in Andorra Lower mortality with HCQ + AZ (p=0.004) c19hcq.org Heras et al., European Geriatric Medic.., Sep 2020 Favors HCQ Favors control

COVID-19 mortality risk factors in older people in a long-term care center

Heras et al., European Geriatric Medicine, doi:10.1007/s41999-020-00432-w (date from preprint)
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 100 COVID+ elderly nursing home patients, HCQ+AZ mortality 11.4% vs. control 61.9%, RR 0.18, p<0.001. Median age 85.
risk of death, 95.6% lower, RR 0.04, p = 0.004, treatment 8 of 70 (11.4%), control 16 of 30 (53.3%), NNT 2.4, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Heras et al., 2 Sep 2020, retrospective, Andorra, peer-reviewed, median age 85.0, 13 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
COVID-19 mortality risk factors in older people in a long-term care center
Eva Heras, Pablo Garibaldi, Maite Boix, Oliver Valero, Jorge Castillo, Yurisan Curbelo, Elso Gonzalez, Obilagilio Mendoza, Maria Anglada, Joan Carles Miralles, Petra Llull, Ricard Llovera, Josep M Piqué
European Geriatric Medicine, doi:10.1007/s41999-020-00432-w
Aim COVID-19 mortality risk factors in older people from a long term care center. Findings Male gender, low Barthel index, no pharmacological treatment and lymphocytopenia are independent mortality risk factors. Message The independent prognostic factors identified in the present study can help to adjust the healthcare resources in this population in case of new outbreaks of the COVID-19 pandemic.
Author contribution EH contributed to the study design, data collection, interpretation of the data, writing and revising the manuscript and accepts responsibility for the corresponding author. PG, MB, JC, YC, EG, OM, MA, JCM, PL, RL contributed to the data collection, data interpretation, and revising of the manuscript. OV carried out the data analysis, data interpretation, and editing of the manuscript. JMP contributed to the interpretation of the data, writing, and revising of the manuscript. All authors read and approved the final manuscript. Compliance with ethical standards Conflict of interest We declare no competing interests. Ethical approval This study was approved by the Research Ethics Committe of the Andorran Healthcare System. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Arons, Hatfield, Redy, Kimball, James et al., Presymptomatic SARS-Cov-2 infections and transmission in a skilled nursing facility, N Eng J Med
Charlson, Pompei, Ales, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis
Chen, Wu, Chen, Yang, Chen, Clinical characteristics of 113 deceassed patients with coronavirus disease 2019: retrospective study, BMJ
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Chowdhury, Rathod, Gernsheimer, A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19, Acad Emerg Med
Corrao, Argano, Natoli, Nobili, Corazza et al., Disability and not diabetes is a strong predictor of mortality in oldest patients hospitalized with pneumonia, Eur J Intern Med
Cortegiani, Ingoglia, Ippolito, Giarratano, Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care
Du, Liang, Yang, Wang, Cao et al., Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study, Eur Respir J, doi:10.1183/13993003.00524-2020
Gal-Oz, Maier, Yoshida, ImmGen report: sexual dimorphism in the immune system transcriptome, Nat Commun, doi:10.1038/s41467-019-12348-6
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Hosmer, Lemeshow, Applied logistic regression 3rd edition
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jin, Bai, He, Wu, Liu et al., Gender differences in patients with COVID-19: focus on severity and mortality, Front Public Health, doi:10.3389/fpubh.2020.00152
Lippi, Plebani, Henry, Thrombocytopenia is associated with severe coronavirus disease 2019(COVID-19) infections: a meta-analysis, Clin Chim Acta
Mahoney, Barthel, Functional evaluation: the Barthel Index, Md State Med J
Mcmichael, Currie, Clark, Pogosjans, Kay et al., Epidemiology of COVID-19 in a longterm care facility in King County, Washington, N Engl J Med
Na, Ding, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Pedersen, Ch, SARS-Cov-2: a storm is raging, J Clin Invest
Qin, Zhou, Hu, Zhang, Yang et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis
Quan, Li, Couris, Fushimi, Graham et al., Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol
Reisberg, Ferris, De Leon, Crook, The global deterioration scale for assessment of primary degenerative dementia, Am J Psychiatry
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquines or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID 19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Shah, Vanclay, Cooper, Improving the sensitivity of the Barthel Index for stroke rehabilitation, J Clin Epidemiol
Tian, Jiang, Yao, Nicholson, Li et al., Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis, J Med Virol, doi:10.1002/jmv.26050
Wang, He, Yu, Hu, Bao et al., Coronavirus disease 2019 in elderly patients: charateristics and prognostic factors based on 4-week follow-up, J Infect
Wang, Li, Barbarino, Gauthier, Dementia care during COVID-19, Lancet
Xiaochen, Shuyun, Muqing, Wang, Tao et al., Risk-factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Allergy Clin Immunol
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult in-patients with COVID-19 in Wuhan, China: a retrospective study, Lancet
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit